Introduction
Cancer arises from an ongoing accumulation of molecular and cellular changes that allows tumour initiation and progression in multicellular organisms (1) . The final cancer phenotype encompasses a broad collection of characteristic features including alterations of the transcriptional profile. Recent investigations have documented changes in the expression of a pattern of genes compared with histologically normal tissues (2, 3) . Some of these alterations can be detected in several types of cancer, whereas others occur in a small subset of tumours only (4) . This has lead to some conflicting conclusions about the number of distinct mechanisms that are required for malignant transformation and the neoplastic phenotype. One of the mechanisms necessary to promote malignancy seems to be the cellular response resulting from the activation of the multiligand receptor for advanced glycation end-products (RAGE) (5) . RAGE is composed of an extracellular region containing three immunoglobulin domains followed by a transmembrane domain and a short cytoplasmic region (6) . Although intracellular binding partners have not yet been identified, this region appears to be essential for RAGE signalling (7, 8) . Several ligands for the engagement of RAGE have been found, including amyloids, advanced glycation end-products, members of the S100 family of calcium-binding proteins, and amphoterin [also known as high-mobility group I DNA binding protein (HMG-1)]. Binding of these ligands to RAGE contributes to perturbation of the cell homeostasis in pathophysiological conditions (9) but also to cell migration and differentiation (10, 11) . Intracellular signalling pathways induced by RAGE include the activation of small GTPases (Cdc42, Rac) (7), mitogen-activated protein kinase (MAPK) and c-Jun N-terminal kinase (JNK) (5), extracellular signal-regulated kinase (ERK)-1/-2 (12) , as well as the activation of transcription factors like nuclear factor (NF)-κB (7) or the cAMP response element-binding (CREB) factor (13) .
In tumour biology, it has been suggested that RAGE engagement through the binding of amphoterin localized outside the cell promotes tumour growth and metastasis (5) . This has been observed in primary C6 glioma cells from rats and in a murine Lewis lung carcinoma model. The major effect of the RAGE-ligand interaction with amphoterin appears to be the migration of, rather than the proliferation of, neoplastic cells, as suggested in studies involving colorectal and pancreatic carcinoma cells (14, 15) . Although the level of RAGE expression correlates directly with the metastatic potential of these tumour cells, there is some conflict about the biological role of RAGE activation in cancer. Studies using neuroblastoma and melanoma cells clearly show that binding of the C-terminal motif of amphoterin to RAGE inhibits the invasive migration in transendothelial migration assays and suppresses the formation of metastasis in vivo (16) . Some of these conflicts may have a basis, firstly, in the fact that RAGE interacts with several extracellular ligands that can be produced by the cell or by neighbouring/circulating cells and therefore influence each other. Moreover, most RAGE ligands also fulfil intracellular functions independent of RAGE. Secondly, all previous studies considered a high level of RAGE and amphoterin in tumours and ignored an altered expression profile that occurred in a large variety of tumours (2, 3, 17) . However, RAGE is highly expressed in a pattern of normal tissues and especially in lung tissue (18) . Therefore, our study aimed to quantify the expression of RAGE in human lung tissue compared with that in non-small cell lung carcinomas (NSCLC). Comparisons with different histological subtypes of NSCLC, tumour stages and degrees of differentiation were intended to give some indication of the biological role of RAGE in lung cancer. Subsequent experimental analyses were created to clarify the effect of human RAGE in a lung carcinoma model in vitro and in vivo.
Material and methods

Patients involved in study
Lung specimens from tumour and paired non-tumour tissue of 34 NSCLC patients, who underwent pulmonary resection surgery, were included in this study, which was approved by the local ethics committee. Patients were grouped according to the size of the primary tumour (T), nodal involvement (N) and distant metastasis (M) to the TNM stages I to IV according to the guidelines of TNM staging (19) . The quantity of cancer cells in tumour samples was estimated by microscopy after hemalumeosin staining (Merck) of the tissue sections. In all cases, specimens were analysed with ≥60% proportion of cancer versus stromal cells. In addition to primary lung cancer, we analysed lung tumours from distant metastasis (n = 2 from kidney, n = 3 from colon), pulmonary lymph nodes, benign lung tumours (i.e. hamartoma, n = 4), and malignant tumours from other organs as given in Table I .
Cell culture conditions and reagents
The lung cancer cell lines used (NCI-H358, NCI-A549, NCI-H322) correspond to NSCLC (ATCC cell bank). Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% foetal bovine serum, 100 units/ml penicillin and 100 µg/ml streptomycin (Invitrogen Life Technology) at 37°C in a 10% CO 2 atmosphere. Collagen was prepared from rat tail in 0.1% acetic acid and layered onto cell culture plates at 2 mg/ml in DMEM. Migration assays were performed using 8 µm pore membrane inserts (Thincerts; Greiner Bio-One), and the number of migrated cells was estimated after AlamarBlue staining (Bioscource). 5-aza-2`deoxycytidine (Sigma), an inhibitor of DNA methylation, was applied at 10 µM for three days and replenished on a daily basis. The efficient inhibition of DNA methylation was controlled by expression analysis of the deleted in liver cancer (DCL-1) mRNA as described recently by Yuan et al. (20) . We used scriptaid at 2.5 µM (Biomol) to inhibit the histone deacetylation (21) .
Construction of expression vectors and transfection
Full-length human RAGE cDNA (XM_004205) and ∆cytoRAGE cDNA (without cytoplasmic domain, aa 367-404) were cloned into the mammalian expression vector pIRES2-EGFP vector (Clontech). Recombinant plasmids or the vector alone were purified with a plasmid isolation kit (Qiagen, CA) and transfected into NCI-H358 cells using Effecten transfection reagent (Qiagen). For stable expression, cells were selected for G418 resistance (Genetecin, 750 µg/ml; Calbiochem) and for green fluorescing protein (GFP) fluorescence using the FACSVantage cell sorter (Becton Dickinson). Immunoblot analysis with the anti-RAGE antibody proved the correct over-expression of each cDNA.
Cell growth
The NCI-H358 cells were harvested from 80% confluent monolayers by brief trypsinization using 0.05% trypsin and 0.5 mM Na 2 EDTA. For proliferation experiments, cells were seeded at a density of 2×10 3 per well of a 12-well tissue-culture plate and cultured for 12 days in regular medium, which was exchanged every four days. Proliferation was estimated at given days by counting the total number of living cells using a Multisizer TM 3 Coulter Counter ® (Beckman Coulter). The cumulative population doubling (CPD) was calculated as: CPD = (ln cell number day x -ln cell number day 1 )/ln2 (22) .
For spheroid culturing, a 5× stock solution of methyl-cellulose (25 mg/ml in DMEM; Sigma) was mixed with NCI-H358 cells to a final number of 500 cells per spheroid and seeded into a single well of a 96-well suspension culture plate. The medium was partially exchanged after five days. Twenty spheroids were cultured per experiment. The diameter of each spheroid was estimated using the Zeiss Axiovert microscope equipped with Metamorph 4.6.5. software (Visitron Systems). Spheroid volumes were calculated as a product of 4/3π*diameter 3 and subsequently averaged.
Reverse transcription-polymerase chain reaction
Isolation of total RNA and cDNA synthesis have been described previously (23 (25) . PCR amplification for analysis of several ligands for RAGE was performed according to the given references (14, 26) . Equal quantity of synthesized cDNA was determined by amplification of 18S rRNA (sense: 5` GTT GGT GGA GCG ATT TGT CTG G 3`; antisense: 5` AGG GCA GGG ACT TAA TCA ACG C 3`). One fifth volume of cDNA reaction was used for PCR containing 1.5 mM MgCl 2 , 5 pmol of each primer, 10 µM of each dNTP, and 1 unit rTaqDNA polymerase (Promega). After PCR amplification and gel-electrophoretic separation, intensity of PCR products was evaluated using the AIDA 2.0 software (Raytest). All mRNA expression values were normalized as ratio per 18S rRNA.
Purification of recombinant RAGE fragments and generation of anti-RAGE antibodies
For generation of a monoclonal mouse anti-RAGE antibody, the internal BamHI sites of human RAGE cDNA were used to subclone the fragment coding for aa 90 to 347 of immature RAGE into the expression vector pQE-32 (Qiagen). Over-expression of the recombinant RAGE fragment with an Nterminal 6×His-tag was performed in E. coli M15p(REP4) (Qiagen), as recommended by the manufacturer. Cells were harvested by centrifugation at 3000×g and 4°C for 10 min and resuspended in 1/25 volume of lysis buffer (8 M urea, 100 mM Na 2 HPO 4 , 10 mM Tris-HCl, pH 8.8; 0.1% Triton X-100, 25 mM imidazole). After brief sonication, cellular debris were pelleted at 13,000×g and 4°C for 30 min. Purification was carried out by mixing the cleared lysate with pre-equilibrated Ni-NTAresin (Qiagen) on a rotator for 1 h, followed by washing four times with lysis buffer and eluting with lysis buffer containing 150 mM imidazole. The purification process was analysed by SDS polyacrylamide gel-electrophoresis, followed by Coomassie Blue staining and immunoblotting using mouse anti-penta-His mAb (Qiagen) as a primary antibody and horseradish peroxidase-conjugated anti-mouse IgG (DAKO) as a secondary antibody. The purified His-tagged RAGE fragment was refolded by stepwise dialysis against buffer (100 mM Na 2 HPO 4 , 10 mM Tris-HCl, pH 7.4; 0.1% Triton X-100), and protein yield was determined by Bradford protein assay (Bio-Rad) after centrifugation at 22,000×g and 4°C for 1 h. The recombinant RAGE fragment was used to immunize BALB/c mice. Hybridomas were generated by the fusion of spleen cells with X-63AG8 myeloma cells according to standard procedures and screened for reactivity with recombinant RAGE fragments by ELISA and immunoblotting. Positive wells were established and cloned twice by limiting dilution. An anti-RAGE monoclonal antibody recognizing recombinant RAGE fragments, bovine RAGE from acetone lung powder (Sigma), and High Five insect cells stably transfected with human full-length RAGE cDNA cloned into pIZ/V5-His vector (Invitrogen) in immunoblots was designated A11 (IgG 2a ). For generation of a polyclonal rabbit anti-RAGE antibody, the intracellular domain of human RAGE (aa 375 to 405) including a C-terminal cysteine residue for coupling was synthesized using fmoc-chemistry with several repeated acylation steps. The peptide was purified by reverse phase chromatography (C18-column) and the peptide was verified by mass spectroscopy. Immunization followed a standard protocol: the KLH-conjugated peptide was injected subcutaneously into rabbits. After 3 weeks the animals were boosted with another amount of the conjugate, and six weeks after immunization the reactivity of the antiserum was tested by immunoblotting using RAGE peptide and lung protein lysate.
Immunoblot analysis
For protein analysis, samples were homogenized in lysis buffer (10 mM Tris-HCl, pH 7.4; 80 mM KCl, 1 mM Na 2 EDTA, 2% SDS) containing complete protease inhibitor (Roche Diagnostics). Protein concentration was measured by the BCA protein assay (Sigma). A total of 50 µg protein was separated by SDS polyacrylamide gel-electrophoresis. In the case of patient tissues, the sample volume was additionally readjusted to an equal protein concentration by the densitometrically determined value of the total protein loading per lane in a Coomassie blue-stained gel. The use of house-keeping proteins does not seem to be reliable for normalization of tumours compared with histologically normal samples, because of the different levels of expression frequently detected (27). Proteins of the analytic gel were blotted onto a nitro-cellulose membrane. Thereafter, the membrane was blocked with 6% non-fat dry milk in TBS-T buffer (200 mM Tris-HCl, pH 7.5; 300 mM NaCl, 0.15% Tween 20) and incubated with the anti-human RAGE antibody (A11; 1:1000 in TBS-T). The monoclonal antibody to the GFP was purchased from Roche Diagnostics. Bound antibodies were visualized by horseradish peroxidase-conjugated secondary antibodies (Dianova) and ECL plus detection (Amersham Bioscience). All analytic gels contained loading samples for internal signal corrections. The intensities of visualized signals were densitometrically analysed and given as optical density units.
Cell-cycle analysis
NCI-H358 cells were always collected at day two after seeding (i.e. start of the exponential growth). Nuclear DNA content was analysed after staining with propidium iodide (PI; Sigma) and subsequent flow cytometry. Briefly, cells were fixed in ice-cold 70% ethanol and incubated with PI solution (50 µg/ml PI, 0.5 mg/ml RNase A, 0.1% sodium citrate, 0.1 mM Na 2 EDTA in PBS; pH 7.2) for 1 h at 4°C. The DNA content of cells was measured using the FACSCalibur flow cytometer equipped with CellQuest Pro software (Becton Dickinson). The number of proliferating cells in the S and G2 cell cycle phase was estimated using the MultiCycle software (Phoenix Flow Systems).
Immunohistochemistry and immunocytochemistry
Lung samples were fixed in buffered 4% formalin and embedded in paraffin. Sections of 8 µm were cut, dewaxed, and rehydrated. Unspecific protein bindings were blocked with 5% bovine serum albumin in PBS. For immunostaining of RAGE, the rabbit antiserum (1:200 in PBS) was applied in a humidified chamber at 37°C for 2 h followed by detection with the LSAB staining system and DAB plus substrate solution (DAKO). Omission of the primary antibody served as a negative control. In the case of NCI-H358 immunofluorescence, cells grown on class coverslips were fixed in 4% formaldehyde for 10 min at 4°C with or without subsequent membrane permeabilization in 0.3% saponin (control with the membrane impermeable nuclear dye Hoechst 33342), they were then blocked with 5% bovine serum albumin and stained for 1 h with the monoclonal mouse primary antibody (A11, 1:400 in PBS) at room temperature. RAGE detection was performed with the Alexa Fluor ® 594 anti-mouse IgG secondary antibody (Molecular Probes Europe) and fluorescence microscopy. Slides were embedded in Mowiol mounting medium (Calbiochem) containing 1% thimerosal (Sigma).
In vivo tumorigenecity assay
Female athymic mice (NMRI-nu) were obtained from Harlan Winkelmann (Borchen, Germany) and maintained under clean room conditions in sterile isolator cages. Xenograft experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals after approval of the local Animal Care Committee. NCI-H358 tumour cells were cultured and harvested from 80% confluent monolayers as described above. 2×10 6 cells per tumour were implanted subcutaneously into the upper flank of the mice. The length and width of the tumours were measured twice a week for the duration of the experiment using a sliding calliper. Tumour volumes were calculated as a product of 4/3π*(length/2)*(width/2) 2 corresponding to the equation of an ellipsoid. Mice were killed at day 29 and tumours were dissected and weighed.
Statistical analysis
For patient analyses, all tumours and the paired control tissue were analysed in one experimental setting with a three-fold determination of RNA and a two-fold detection of protein samples for each patient. The Student's paired t test was used for statistical comparison of both evaluation groups. The ANOVA procedure was applied for multiple comparisons followed by the Tukey test in the case of pairwise analyses. Dunnett's test was used for the evaluation to a control group in the case of experimental investigations. Regression analyses were carried out and the coefficients of each proliferation or growth curve were calculated according to the given formula and subsequently subjected to multiple analyses (SigmaStat and SigmaPlot software; Jandel Corp., San Rafael, CA). All data are reported as mean ± S.E.M. (n ≥ 3 in all cases), and P values less than 0.05 were accepted as indicating a significant difference.
Results
RAGE expression in lung cancer and other tumours
Investigations of the RAGE expression revealed that the mRNA level of RAGE is markedly decreased in tumour samples of NSCLC patients. The overall mRNA expression was similarly down-regulated in squamous cell lung carcinoma (SCCa) and adenocarcinoma (AdCa) compared with non-tumour control lung tissue derived from the same patient ( Figure 1A) . These data were confirmed on a protein level (Figure 2) . Although there was less expression of RAGE in NSCLC patients with TNM stage III to IV than in TNM I patients (Figure 3) , the altered expression is not related to the malignant phenotype in general. Lung tumours from the benign neoplasm (hamartoma) were also characterized by a strongly reduced RAGE level ( Figure 1A ) and the low expression of RAGE in NSCLC was shown to depend on the tumour differentiation stage. However, detailed analysis did not reveal differentiation-dependent changes of the RAGE mRNA values with 2.47±1.09 in stage II NSCLC (n = 11) and 2.20±0.87 in stage III NSCLC (n = 23). Because lung tissue is a major source of RAGE expression (18), we also analysed tumour specimens derived from other organs as well as the paired non-tumour control. As demonstrated in Figure 1B , the level of RAGE is commonly reduced in different types of solid tumours. Metastases from distant tumours revealed a clear RAGE reduction compared with individual lung specimens ( Figure 1A ). These descriptive investigations clearly show that the down-regulation of RAGE seems to be a common event in neoplastic tissues.
In addition to the receptor RAGE, secretory RAGE isoforms exist that lack the transmembrane domain (24) . Therefore, it might be possible that reduced levels of full-length RAGE in NSCLC result from a differential transcription of the RAGE gene towards one of those secretory isoforms. However, the isoform-specific PCR analysis showed that not only the receptor but also the sRAGE1 splice variant is down-regulated in most lung tumours (for example see Figure 1C ). While the sRAGE1 mRNA is always detectable, the expression of the soluble RAGE variants, sRAGE2 and sRAGE3, is less induced in tumours. A direct PCR quantification of the secretory isoforms per RAGE is, however, not possible and is misleading because of the competitive amplification of the PCR products. In contrast to these C-terminally modified isoforms, transcription of the RAGE variant lacking the Nterminal extracellular domain (25) cannot be detected (data not shown).
Blockade of the gene transcription by aberrant promoter methylation is a hallmark of cancer progression (1) . Therefore, we treated the lung adenocarcinoma cell line NCI-H358 with 5-aza-2`deoxycytidine (5-Az-2`DC), an inhibitor of the methylation process. As a positive control we proved the transcription of the novel C-type lectin receptor (DCL-1), which is diminished in lung neoplasms as a result of DNA hypermethylation but can be reinduced by 5-Az-2`DC in a pattern of cell lines (20) . While DCL-1 transcription is also activated in NCI-H358 cells, RAGE mRNA expression cannot be reinduced in the presence of 5-Az-2`DC ( Figure 3) . Moreover, inhibition of the histone deacetylation is frequently used as an activator of transcription. However, blockade of the deacetylation with scriptaid (28) alone or in combination with 5-Az-2`DC did not result in the transcriptional reinduction of RAGE (data not shown). These experimental data suggest that downregulation of RAGE in NSCLC does not result from typical changes during tumour progression.
While assessing which of the known RAGE ligands are expressed in lung tissue and whether there is a broad failure of the RAGE pathway in NSCLC, we proved the expression of amphoterin, S100A1, S100A12, S100B and S100P. Using PCR analysis the mRNA of amphotherin, S100A1 and S100P in human lung tumours and normal lung tissues can be detected, but S100B and S100A12 mRNA are not expressed (data not shown).
Proliferation of RAGE-expressing lung cancer cells in vitro and in vivo
On the basis of the low level of RAGE in NSCLC and other neoplasms, it might be that downregulation of RAGE supports tumour growth. Therefore, we performed in vitro experiments to study the impact of RAGE on the proliferation of lung cancer cells. Initially, we tested the RAGE level in different human lung cancer cell lines (NCI-H322, NCI-A549, and NCI-H358). All cell lines were characterized by a low level of RAGE mRNA and even missing protein expression, compared with human lung tissue (data not shown). Finally, we chose NCI-H358 for over-expression of full-length human RAGE and of ∆cytoRAGE that lacks the cytosolic domain ( Figure 4A ). The stable expression of RAGE and ∆cytoRAGE cDNA in NCI-H358 had no influence on the level of amphoterin and S100A1 in vitro as determined by PCR analysis (data not shown). As demonstrated in Figure 4B , over-expression of RAGE resulted in a diminished proliferation of NCI-H358 in vitro. DNA analyses confirmed this observation, detecting a lower number of cells in the S and G2 cell cycle phase for RAGE-transfected NCI-H358 compared with mock control cells ( Figure 4C ).
Cell behaviour and proliferation might be strongly coupled with cell-cell contacts and, consequently, we established a 3-dimensional spheroid cell culture to investigate the proliferation of tumour cells in a more cancer-related in vitro model. Here we also observed diminished growth of RAGE-transfected cells compared with mutant ∆cytoRAGE NCI-H358 ( Figure 5A) . Surprisingly, the spheroid growth of mock-transfected control cells was not significantly altered, as seen in monolayer cultures ( Figure 5A ). The subcutaneous implantation of NCI-H358 lung cancer cells confirmed this observation showing that tumours of RAGE-transfected cells developed more slowly than those of ∆cytoRAGE-expressing cells, but they were not different from mock controls ( Figure 5B ). These data imply that RAGE re-expression in cancer cells does not exclusively impair the tumour growth. Rather, it suggests that more factors are necessary for RAGE signalling which are actively neutralized in mutant ∆cytoRAGE cells but not in normal NCI-H358 cells.
Cell morphology and subcellular localization of RAGE
Epithelial cells in the airways of the lung are attached to the basal lamina, a fibre network consisting of several extracellular compounds including collagen. Therefore, we cultured NCI-H358 cells on collagen layers and observed a spreading, epithelial-like growth of RAGE-and ∆cytoRAGE-expressing cells that has not been seen for NCI-H358 controls ( Figure 6 ). The observation can be confirmed for the spheroid culturing of RAGE-and ∆cytoRAGE-expressing cells which, when placed on non-coated plastic dishes, start spreading after 7 to 10 days. This may be explained by accumulation of extracellular matrix compounds that are produced by the cell itself. However, overexpression of RAGE did not induce increased cell migration across a pore membrane as assessed by in vitro migration assays, whereas ∆cytoRAGE transfection did (data not shown).
Subsequently, immunocytochemistry was performed to determine the localization of RAGE in NCI-H358 cells. Fluorescence microscopy after staining with an antibody directed against the extracellular domain showed a strong membrane localization in single cells along with a clear redistribution of RAGE towards intercellular contact sites at higher cell densities (Figure 7 ; series I). The surface distribution of RAGE frequently appears scattered without a distinct boundary around the cell. This scattered RAGE staining can be detected with and without cell permeabilization, suggesting its clear membrane localization. Although the cytosolic domain is lacking in ∆cytoRAGE-expressing cells, the truncated receptor is also preferentially localized at the cell-cell contacts (Figure 7 ; series II). NCI-H358 control cells were almost negative in RAGE staining as already determined by immunoblotting ( Figure 4A ). Altogether, this observation suggests that RAGE signalling is not required for the formation of intercellular contacts.
Discussion
Recent application of transcriptional profiling to cancer diseases has documented large numbers of differentially expressed genes in tissues that are derived from cancer patients, compared with those from healthy individuals or histologically normal tissues from the same individual (2, 3) . This observation has been made for many types of tumours including lung carcinomas (29) . In the present study we demonstrated that the multiligand receptor RAGE is one of those genes differentially expressed in NSCLC. In paired samples derived from tumour tissue and histologically normal tissue from the same patient, RAGE expression is strongly reduced on mRNA and more strongly reduced or even missing on the protein level in lung tumours. Moreover, the down-regulation of RAGE mRNA is especially related to patients with a high cancer stage (TNM stage III-IV carcinoma). Investigations of tumour samples and metastases derived from other origins also revealed a reduced level of RAGE in neoplastic tissues suggesting that the down-regulation of RAGE is not restricted to lung neoplasms. Recently, Schenk et al. identified polymorphisms in the promoter region of the RAGE gene that are associated with NSCLC (30) . However, these differences in genotype can only be detected in a subset (21%) of NSCLC patients which does not correlate with the common transcriptional down-regulation of RAGE observed. Because RAGE transcription is mainly under control of NF-κB, which is induced in cancer (31), a down-regulation of the corresponding transcription factor cannot be responsible for the lower level of RAGE mRNA expression in tumours. A further hallmark of cancer is the blockade of gene transcriptions by aberrant DNA methylation (1), which is why we investigated whether an indirect inhibition of the DNA hypermethylation with 5-aza-2`deoxycytidine can reinduce the RAGE mRNA expression. However, inhibition of DNA methylation, neither alone nor in combination with the histone deacetylase inhibitor, scriptaid, was sufficient to reinduce the RAGE transcription in a human lung cancer cell line.
As already mentioned, the decrease in RAGE protein seems to be more pronounced than the mRNA reduction, suggesting further post-transcriptional regulation. In this context, several truncated isoforms of RAGE have also been identified (24, 25) . The differential splicing process of the precursor RAGE mRNA results in a transmembrane-spanning N-truncated and several C-truncated (secretory) isoforms of RAGE which can contribute to a divergent cellular response. Nonetheless, a strongly changed alternative splicing towards one of those isoforms cannot be detected in lung tumours compared with normal lung. While lower RAGE expression due to reduced levels of the geneactivating transcription factors, NF-κB and Sp-1 (32), are unlikely in cancer cells, an active repression of the RAGE expression or other post-transcriptional mechanisms are possible as well. In the latter case, Caballero et al. have recently identified a second polyadenylation sequence in the 3´-untranslated region of the RAGE gene generating a mRNA isoform with an adenylate plus timidylate rich element (ARE) that contributes to a fast degradation of the RAGE mRNA (33) .
The major ligand of RAGE in the lung might be amphoterin, which is also highly expressed in lung tissue. Amphoterin is a high-mobility group I non-histone DNA-binding protein (HMG-1) that can be secreted into the extracellular space during certain stages of development (34) or in necrotic cells where it triggers inflammation (35) . Moreover, amphoterin is secreted in response to the proinflammatory stimulation of cells with cytokines (36) or endotoxin (37) . Although it is unclear to what extent amphoterin is located in the extracellular space of tumour cells, the interaction of amphoterin with RAGE has been suggested to contribute to tumour growth and especially to invasive migration and metastasis (5, 38) . However, none of the studies using experimental settings consider RAGE to be differentially expressed in tumours compared with the corresponding normal tissues, as was suggested by Schraml et al. some years ago (39) . On the basis of this and our observations, whether RAGE takes over this special function in cancer biology as interpreted is speculation. Although it has been observed that RAGE levels correlate with the invasive behaviour of gastric cancer cells, we also detected a lower level of RAGE expression in primary tumours derived from the colon and rectum. Moreover, the low degree of RAGE expression in metastatic tissue from gastric cancers and other metastases, as well as the reduction of RAGE in benign tumours, contradicts the biological function of RAGE activation in metastasis. In this context, our clinical data, as well as a non-increased migration of RAGE-expressing lung cancer cells (NCI-H358) in vitro, support the observation of Huttunen et al. that RAGE activation does not contribute to the tumour cell migration (16) .
For further elucidation of the down-regulation of RAGE in tumours we analysed the proliferation of NCI-H358 cells stably over-expressing RAGE and the cytoplasmic domain deletion variant ∆cytoRAGE. Through study of monolayer cultures, we revealed a diminished proliferation of RAGEexpressing cells in vitro. Our findings are consistent with data from a neuroblastoma cell model showing that full-length RAGE, but not the cytosol-deleted RAGE, mediates the arrest of proliferation after receptor activation (13) . Therefore, these results initially suggest a tumour-suppressive action of RAGE in lung cancer. In vitro spheroid cultures and in vivo tumorigenecity assays in athymic mice confirmed that lung cancer cells over-expressing RAGE also form smaller tumours compared with ∆cytoRAGE. However, they did not differ from normal NCI-H358 cells as observed in the monolayer cell cultures. Despite the differences between 2-and 3-dimensional cell proliferation, we did not observe increased tumour formation in the presence of RAGE as has been seen for C6 glioma cells after injection into athymic mice (5) or for melanoma cells in vitro (40) . On the contrary, we observed a better tumour growth through the blockage of RAGE signalling via the cytoplasmic domain deletion mutant ∆cytoRAGE NCI-H358. These conflicting observations in lung cancer cells clearly suggest a more complex network in response to RAGE-ligand interactions that is still poorly understood. In our study we have shown that several RAGE ligands like amphotherin, S100A1 and S100P are expressed in lung cancer cells whereas other are not detectable (S100B, S100A12). Taking into account the fact that RAGE can be activated by those ligands, there might be a synergistic effect between the proinflammatory action on the one hand and the pro-survival effect on the other, as described for RAGEbinding S100 proteins and amphoterin (34, 41, 42) . It is also the case that the extracellular level and the constitution of RAGE-binding ligands might be dependent on the location of tumour cells and the microenvironment. Moreover, it has to be remembered that all known ligands of RAGE fulfil intraand extracellular functions independent of RAGE (34, 41) . The induced expression of RAGE in cancer cells might change this balance to an unknown degree as a result of a preferredreceptor interaction in the over-expressing cells. Hier Liganden einfügen Despite some conflicts regarding the importance of RAGE in tumour growth and invasive behaviour, it has to be borne in mind that the level of RAGE is greatly reduced in malignant tumours derived from lung and other organs, and in benign tumours as well. Based on immunocytochemistry (that demonstrates a preferential localization of RAGE at the cell-cell contacts) the down-regulation of RAGE in tumours may be considered as a critical step in the tissue reorganization during tumour formation. Moreover, this intercellular localization clearly depends on the extracellular RAGE domain and can also be observed for mutant ∆cytoRAGE.
In adults, normal epithelial cells are polarized and organized broadly into squamous sheets or secretory structures via intercellular attachments. Recently, the receptor RAGE has been identified as a marker protein for type I lung alveolar (ATI) cells which are polarized (43) . RAGE is localized at the basolateral membrane of ATI cells and co-localizes with the ERBB2/HER2 receptor interacting protein (ERBIN), another basolateral protein important for epithelial organization (44) . Moreover, RAGE expression is enhanced in parallel to the differentiation of ATI cells (44, 45) . Given that RAGE is associated with differentiation, cell polarity and organization of the epithelium, its decrease in lung tumours might contribute to the loss of polarization and differentiation. This assumption is strongly supported by our observation that RAGE contributes to cell growth as an epithelial layer on collagen, a major compound of the epithelial basement membrane. In contrast, RAGE-deficient lung cancer cells preferentially proliferate as a multicellular complex. Along with the detection of RAGE, and ∆cytoRAGE, at the intercellular contact sites, this epithelial cell arrangement seems not to be dependent on the expression of the intracellular RAGE domain. This suggests that there are more extracellular factors and/or surface membrane compounds that contribute (in combination with RAGE) to an epithelial cell organization.
In summary, our findings indicate that down-regulation of RAGE in human NSCLC might contribute to the loss of epithelial tissue structure and concomitant oncogenic transformation without restriction of cell proliferation in epithelial carcinomas. . Spheroid growth was evaluated by estimating the mean volume at given days which shows a reduced size of RAGE but not of ∆cytoRAGE expressing spheroids. *P < 0.05 versus RAGE for the mean coefficient a calculated from the regression for each experiment (n = 8). (B) Increased tumour growth of ∆cytoRAGE-transfected NCI-H358 cells after subcutaneous injection into athymic mice. *P < 0.05 indicates differences for the mean coefficient a calculated from the regression of ∆cytoRAGE and RAGE cells (n ≥ 7). Final tumour weight additionally indicates larger tumours derived from ∆cytoRAGE-expressing NCI-H358 as well. *P < 0.05 versus RAGE tumours and mock controls. Fig. 6 . NCI-H358 cells were cultured on tissue culture dishes without (a, 2 days) and with collagen layer (b, 2 days; c, 5 days). Mock NCI-H358 cells (I series) grew in a rounded shape, whereas cells over-expressing RAGE (II series) and ∆cytoRAGE (III series) showed a spread growth on collagen. Ic) . Although the cytosolic domain is lacking in ∆cytoRAGE expressing cells, the truncated receptor is also preferentially localized at the cell-cell contact sites (IIb, IIc).
Figure legends
